126 related articles for article (PubMed ID: 32317518)
1. HER-2/neu over expression in gall bladder adenocarcinoma: A quest for potential therapeutic target.
Jain P; Goyal S; Chauhan G; Majumdar K; Ali S; Sakhuja P; Agarwal AK
Indian J Pathol Microbiol; 2020; 63(2):214-220. PubMed ID: 32317518
[TBL] [Abstract][Full Text] [Related]
2. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hammock L; Lewis M; Phillips C; Cohen C
Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
[TBL] [Abstract][Full Text] [Related]
3. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
Lateef F; Jamal S; Nasir S
J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
[TBL] [Abstract][Full Text] [Related]
5. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
6. Expression of ER, PR, and HER-2 Neu and correlation with tumor markers in gall bladder carcinoma.
Mani R; Gupta A; Gupta S; Goyal B; Mishra R; Tandon A; Sharma O; Rohilla KK; Kishore S; Dhar P
J Cancer Res Ther; 2023; 19(5):1279-1287. PubMed ID: 37787296
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer.
Shukla P; Mishra K; Shukla R; Vishwakarma R; Kumari N; Krishnani N; Behari A; Kapoor VK
J Cancer Res Ther; 2024 Jan; 20(1):349-357. PubMed ID: 38554345
[TBL] [Abstract][Full Text] [Related]
8. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
10. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
[TBL] [Abstract][Full Text] [Related]
11. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
12. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay.
Goud KI; Dayakar S; Vijayalaxmi K; Babu SJ; Reddy PV
Indian J Med Res; 2012 Mar; 135(3):312-7. PubMed ID: 22561616
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
16. Expression of VEGF-A, HER2/neu, and
Singh P; Jain SL; Sakhuja P; Agarwal A
Indian J Pathol Microbiol; 2021; 64(4):687-692. PubMed ID: 34673587
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
Kokate P; Sawaimoon S; Bhatia S; Mandava S
Genet Test Mol Biomarkers; 2012 Apr; 16(4):239-45. PubMed ID: 22023243
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
[TBL] [Abstract][Full Text] [Related]
19. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
[TBL] [Abstract][Full Text] [Related]
20. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.
de Pinieux G; Colin D; Vincent-Salomon A; Couturier J; Amsellem-Ouazana D; Beuzeboc P; Vieillefond A
Virchows Arch; 2004 May; 444(5):415-9. PubMed ID: 15029496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
